NYVEPRIA
Biological
PFIZER INC.
Total Payments
$9.5M
Transactions
53
Doctors
10
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $363,225 | 3 | 0 |
| 2022 | $9.2M | 40 | 0 |
| 2021 | $133.14 | 7 | 7 |
| 2020 | $9,600 | 3 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.5M | 46 | 100.0% |
| Food and Beverage | $133.14 | 7 | 0.0% |
Payments by Type
Research
$9.5M
46 transactions
General
$133.14
7 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 1 OPENLABEL RANDOMIZED SINGLE DOSE 2WAY CROSSOVER STUDY ASSESSING PHARMACOKINETIC COMPARABILITY OF TWO PF06881894 PRESENTATIONS ONBODY INJECTOR AND PREFILLED SYRINGE IN HEALTHY PARTICIPANTS | PFIZER INC. | $9.5M | 0 |
| BIOSIMILARS ONCOLOGY CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $9,600 | 3 |
Top Doctors Receiving Payments for NYVEPRIA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $9.5M | 43 |
| , M.D | Internal Medicine | Miami, FL | $3,200 | 1 |
| , M.D | Family Medicine | Jacksonville, FL | $3,200 | 1 |
| , MD PHD | Internal Medicine | Fort Lauderdale, FL | $3,200 | 1 |
| , M.D | Oncology | Carolina, PR | $26.64 | 1 |
| , MD | Hematology & Oncology | Caguas, PR | $17.75 | 1 |
| , MD | Hematology & Oncology | Caguas, PR | $17.75 | 1 |
| , MD | Hematology & Oncology | Caguas, PR | $17.75 | 1 |
| , M.D | Hematology & Oncology | Aguas Buenas, PR | $17.75 | 1 |
| , MD | Hematology & Oncology | Caguas, PR | $17.75 | 1 |
| , MD | Hematology & Oncology | Caguas, PR | $17.75 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $9.5M
- PBG PUERTO RICO LLC $133.14
Product Information
- Type Biological
- Total Payments $9.5M
- Total Doctors 10
- Transactions 53
About NYVEPRIA
NYVEPRIA is a biological associated with $9.5M in payments to 10 healthcare providers, recorded across 53 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2020 to 2023. In 2023, $363,225 was paid across 3 transactions to 0 doctors.
The most common payment nature for NYVEPRIA is "Unspecified" ($9.5M, 100.0% of total).
NYVEPRIA is associated with 2 research studies, including "A PHASE 1 OPENLABEL RANDOMIZED SINGLE DOSE 2WAY CROSSOVER STUDY ASSESSING PHARMACOKINETIC COMPARABILITY OF TWO PF06881894 PRESENTATIONS ONBODY INJECTOR AND PREFILLED SYRINGE IN HEALTHY PARTICIPANTS" ($9.5M).